Claim: Crisaborole blocks the release of certain cytokines involved in the inflammation process such as tumor necrosis factor alpha by blocking their release, it is expected to ease the inflammation and relieve symptoms of the disease.
Evidence: Crisaborole blocks the release of certain cytokines involved in the inflammation process such as tumor necrosis factor alpha, interleukins (IL‑2, IL-4, IL-5), and interferon gamma. By blocking their release, crisaborole is expected to ease the inflammation and therefore relieve symptoms of the disease.